Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GYCJG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
XB-002
|
|||||
| Synonyms |
ICON-2; XB 002; XB002; XB002 Tissue Factor ADC
Click to Show/Hide
|
|||||
| Organization |
Iconic Therapeutics, Inc.; Exelixis, Inc.; Exelis, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 13 Indication(s)
Adenocarcinoma [ICD11:2D40]
Phase 1
Bladder cancer [ICD11:2C94]
Phase 1
Fallopian tube cancer [ICD11:2C74]
Phase 1
Head and neck cancer [ICD11:2B60-2B6E]
Phase 1
Krukenberg tumour [ICD11:XH3RD4]
Phase 1
Laryngeal cancer [ICD11:2C23]
Phase 1
Mouth neoplasm [ICD11:2E90]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Pancreatic cancer [ICD11:2C10]
Phase 1
Peritoneal cancer [ICD11:2C51]
Phase 1
Squamous cell cancer [ICD11:2D60-2D61]
Phase 1
Urothelial cancer [ICD11:2C9Z]
Phase 1
Uterine cancer [ICD11:2C78]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
3.3
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Tissue factor (F3)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.